FDA-approved Abl/EGFR/PDGFR kinase inhibitors show potent efficacy against pandemic and seasonal influenza A virus infections of human lung explants
- PMID: 36968089
- PMCID: PMC10034449
- DOI: 10.1016/j.isci.2023.106309
FDA-approved Abl/EGFR/PDGFR kinase inhibitors show potent efficacy against pandemic and seasonal influenza A virus infections of human lung explants
Abstract
Influenza viruses (IVs) cause substantial global morbidity and mortality. Given the limited range of licensed antiviral drugs and their reduced efficacy due to resistance mutations, repurposing FDA-approved kinase inhibitors as fast-tracked host-targeted antivirals is an attractive strategy. We identified six FDA-approved non-receptor tyrosine kinase-inhibitors (NRTKIs) as potent inhibitors of viral replication of pandemic and seasonal IVs in vitro. We validated their efficacy in a biologically and clinically relevant ex vivo model of human precision-cut lung slices. We identified steps of the virus infection cycle affected by these inhibitors and assessed their effect(s) on host responses. Their overlapping targets suggest crosstalk between Abl, EGFR, and PDGFR pathways during IAV infection. Our data and established safety profiles of these NRTKIs provide compelling evidence for further clinical investigations and repurposing as host-targeted influenza antivirals. Moreover, these NRTKIs have broad-spectrum antiviral potential given that their kinase/pathway targets are critical for the replication of many viruses.
Keywords: Cell biology; Virology.
© 2023 The Authors.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
![None](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/10034449/bin/fx1.gif)
![Figure 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/10034449/bin/gr1.gif)
![Figure 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/10034449/bin/gr2.gif)
![Figure 3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/10034449/bin/gr3.gif)
![Figure 4](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/10034449/bin/gr4.gif)
![Figure 5](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/10034449/bin/gr5.gif)
![Figure 6](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/10034449/bin/gr6.gif)
![Figure 7](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/10034449/bin/gr7.gif)
Similar articles
-
FDA-Approved Inhibitors of RTK/Raf Signaling Potently Impair Multiple Steps of In Vitro and Ex Vivo Influenza A Virus Infections.Viruses. 2022 Sep 16;14(9):2058. doi: 10.3390/v14092058. Viruses. 2022. PMID: 36146864 Free PMC article.
-
Repurposing Kinase Inhibitors as Antiviral Agents to Control Influenza A Virus Replication.Assay Drug Dev Technol. 2015 Dec;13(10):638-49. doi: 10.1089/adt.2015.0003.drrr. Epub 2015 Jul 20. Assay Drug Dev Technol. 2015. PMID: 26192013 Free PMC article.
-
Identification and Characterization of Novel Compounds with Broad-Spectrum Antiviral Activity against Influenza A and B Viruses.J Virol. 2020 Mar 17;94(7):e02149-19. doi: 10.1128/JVI.02149-19. Print 2020 Mar 17. J Virol. 2020. PMID: 31941776 Free PMC article.
-
Kinase Inhibitors as Potential Therapeutic Agents in the Treatment of COVID-19.Front Pharmacol. 2022 Apr 4;13:806568. doi: 10.3389/fphar.2022.806568. eCollection 2022. Front Pharmacol. 2022. PMID: 35444538 Free PMC article. Review.
-
Response Modifiers: Tweaking the Immune Response Against Influenza A Virus.Front Immunol. 2019 Apr 12;10:809. doi: 10.3389/fimmu.2019.00809. eCollection 2019. Front Immunol. 2019. PMID: 31031778 Free PMC article. Review.
Cited by
-
The Raf kinase inhibitors Dabrafenib and Regorafenib impair Zika virus replication via distinct mechanisms.J Virol. 2024 Aug 20;98(8):e0061824. doi: 10.1128/jvi.00618-24. Epub 2024 Jul 18. J Virol. 2024. PMID: 39023323 Free PMC article.
-
Precision cut lung slices: an integrated ex vivo model for studying lung physiology, pharmacology, disease pathogenesis and drug discovery.Respir Res. 2024 Jun 1;25(1):231. doi: 10.1186/s12931-024-02855-6. Respir Res. 2024. PMID: 38824592 Free PMC article. Review.
-
Host Responses to Respiratory Syncytial Virus Infection.Viruses. 2023 Sep 26;15(10):1999. doi: 10.3390/v15101999. Viruses. 2023. PMID: 37896776 Free PMC article. Review.
References
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous